US Patent 11,026,931: Valbenazine Patent Scope, Claim Analysis, Orange Book Status, and Generic Entry Risk
US Patent 11,026,931 protects a specific clinical-use protocol for valbenazine, the active ingredient in Ingrezza. Its claims do not broadly cover valbenazine, all VMAT2 inhibitors, or every use of valbenazine in tardive dyskinesia. They target treatment protocols that combine valbenazine administration with monitoring for hypersensitivity reactions and discontinuation decisions, including a 40 mg-to-80 mg once-daily titration regimen.
The patent is strategically important because the claimed dosing and monitoring steps correspond closely to the FDA-approved Ingrezza treatment paradigm. The patent is a method-of-use asset, not a basic compound, salt, formulation, or manufacturing patent.
What drug does US Patent 11,026,931 protect?
The claimed VMAT2 inhibitor is valbenazine, chemically identified in the claims by its long systematic name. The claims cover valbenazine free base and pharmaceutically acceptable salts, with specific dependent claims directed to valbenazine ditosylate and polymorphic Form I.
| Item |
Patent relevance |
| Active ingredient |
Valbenazine |
| Commercial product |
Ingrezza |
| Developer and principal marketer |
Neurocrine Biosciences |
| Pharmacologic class |
VMAT2 inhibitor |
| Approved indication relevant to the claims |
Tardive dyskinesia |
| Claimed dosage forms |
Tablet or capsule |
| Claimed doses |
40 mg, 60 mg, and 80 mg valbenazine free-base equivalent once daily |
| Specific salt |
Valbenazine ditosylate |
| Specific solid form |
Dit tosylate polymorphic Form I |
| Claim category |
Method of treatment and treatment monitoring |
The claim text contains typographical variants such as "3 sobutyl." Those references are understood in context as the same isobutyl-substituted valbenazine structure used throughout the claims.
What are the independent claims in US Patent 11,026,931?
The patent has three principal independent claim groups: claims 1, 11, and 23.
Claim 1: fixed-dose treatment with hypersensitivity monitoring
Claim 1 requires all of the following:
- Treating a patient with tardive dyskinesia.
- Administering valbenazine or a pharmaceutically acceptable salt.
- Administering an amount equivalent to approximately 40 mg, 60 mg, or 80 mg of valbenazine free base once daily.
- Monitoring for exposure-related adverse reactions.
- Discontinuing treatment based on the patient’s ability to tolerate the reaction.
- The adverse reaction being a hypersensitivity reaction.
Claims 2 through 10 narrow this group by specifying the dose, dosage form, salt, polymorphic form, and particular hypersensitivity events.
Claim 11: response-based continuation or discontinuation
Claim 11 covers a treatment decision process:
- orally administering a first therapeutically effective amount of valbenazine;
- monitoring for exposure-related hypersensitivity reactions;
- discontinuing if the reaction is present; and
- continuing at the same or an increased amount if the reaction is absent.
This claim is broader than claim 1 as to the initial dose because it does not itself specify 40 mg, 60 mg, or 80 mg. The dependent claims add those dose limitations.
Claim 23: one-week 40 mg-to-80 mg titration
Claim 23 covers:
- administering approximately 40 mg once daily for one week;
- increasing to approximately 80 mg once daily after one week;
- monitoring for hypersensitivity reactions; and
- discontinuing based on tolerability.
This is the most commercially significant claim group because it tracks the central dose-escalation schedule described in the Ingrezza prescribing information for many patients with tardive dyskinesia.[2]
What is the core scope of the patent claims?
The claims combine four elements that must be assessed together:
| Claim element |
Scope |
| Disease |
Tardive dyskinesia |
| Drug |
Valbenazine or a pharmaceutically acceptable salt |
| Administration |
Oral, once-daily dosing in specified embodiments |
| Clinical management |
Monitoring for hypersensitivity and discontinuing or continuing treatment based on the result |
A valbenazine product alone does not necessarily practice the claims. Infringement analysis depends on whether the claimed treatment method is performed. The relevant conduct may include prescribing, labeling, instruction, and actual administration, depending on the asserted infringement theory and the facts of the case.
The patent does not claim:
- valbenazine as a chemical compound in the abstract;
- the valbenazine molecule for every therapeutic use;
- every dose of valbenazine;
- every formulation of valbenazine;
- treatment of Huntington’s disease or other movement disorders;
- manufacturing valbenazine or valbenazine ditosylate;
- a composition claim covering every tablet containing valbenazine; or
- hypersensitivity monitoring independent of valbenazine treatment.
How do the dependent claims narrow the patent?
The dependent claims create several commercially relevant fallback positions.
Dose limitations
Claims 2 through 4 specify 40 mg, 60 mg, and 80 mg once-daily regimens. Claims 16 through 21 separately specify first and second therapeutically effective amounts at those dose levels.
The 40 mg and 80 mg claims are more commercially important than the 60 mg claims because the standard Ingrezza dosing structure generally begins at 40 mg and may increase to 80 mg after one week. The 60 mg strength is relevant to dose modification and commercial product presentation but is not the central titration sequence in claim 23.
Salt and solid-form limitations
Claims 6 through 8, 13 through 15, and 24 through 26 cover:
- valbenazine salts;
- valbenazine ditosylate; and
- ditosylate polymorphic Form I.
These limitations provide a narrower path to validity and infringement. They may be useful if a generic product uses the same salt or solid form, but they do not necessarily reach a product using a different pharmaceutically acceptable salt or a different crystalline form.
Dosage-form limitations
Claims 5 and 12 specify tablets or capsules. These claims are directed to commercially practical oral dosage forms, but the independent claims are not uniformly limited to a tablet or capsule. A generic oral product could therefore require separate analysis under the broader claims and the dosage-form-dependent claims.
Hypersensitivity limitations
Claims 9, 10, and 22, as well as claims 27 through 30, specify hypersensitivity reactions including:
- allergic dermatitis;
- angioedema;
- pruritus; and
- urticaria.
The claims do not require that hypersensitivity actually occur in every patient. Several claims are structured around monitoring for the presence or absence of a reaction and taking a treatment decision based on that result. That drafting structure is important in assessing label-based infringement.
What is the likely patent term and expiration date?
US Patent 11,026,931 issued on June 8, 2021. Based on the patent-family filing history and the standard 20-year term measured from the earliest effective nonprovisional filing, the patent is expected to expire in approximately March 2038, subject to any applicable patent-term adjustment or terminal-disclaimer effects.[1]
The precise enforceable expiration date should be taken from the current USPTO patent record and the applicable Orange Book entry. Patent expiration does not itself establish whether the patent remains enforceable against a specific generic product. Terminal disclaimers, patent-term adjustment, patent-term extension, disclaimers, and litigation outcomes can affect the practical exclusivity analysis.
What is the Orange Book status of US Patent 11,026,931?
US Patent 11,026,931 is associated with Ingrezza, whose active ingredient is valbenazine. Its relevance to the Orange Book is based on method-of-use protection for tardive dyskinesia dosing and treatment management.
An Orange Book listing generally gives the NDA holder a mechanism to assert the patent after receipt of an abbreviated new drug application containing a Paragraph IV certification. The listing does not mean that every possible generic product infringes every claim. It means the listed patent has been identified as relevant to the approved product under FDA listing rules.[3]
The practical implications are:
- A generic applicant may be required to address the listed patent in its ANDA certification.
- A Paragraph IV notice may trigger patent litigation.
- A timely infringement action may create a statutory approval stay of up to 30 months, subject to statutory exceptions and court developments.
- A section viii statement may be available for claims that are not relevant to the generic applicant’s proposed labeling, although the viability of that approach depends on the exact Orange Book use code and proposed indication.
Because the patent claims concern treatment of tardive dyskinesia, a generic applicant seeking approval for the same indication may face a direct use-code and labeling challenge.
How strong is the patent estate for Ingrezza?
Patent 11,026,931 is one layer of the Ingrezza estate. The commercial protection strategy for valbenazine has included several categories:
| Patent category |
Typical protected subject matter |
Relevance to generic entry |
| Composition-of-matter patents |
Valbenazine chemical structure and stereochemistry |
Broadest molecule-level protection |
| Salt patents |
Valbenazine ditosylate and related salts |
Relevant to the commercial active form |
| Polymorph patents |
Crystalline Form I and other solid forms |
Relevant to manufacturing and product composition |
| Formulation patents |
Tablets, capsules, excipients, release characteristics |
Relevant to finished dosage forms |
| Method-of-use patents |
Tardive dyskinesia, dosing, titration, monitoring |
Relevant to ANDA labeling and induced infringement |
| Manufacturing patents |
Synthesis, purification, crystallization |
Relevant to supply and process replication |
Patent 11,026,931 is strongest when the accused product’s labeling expressly instructs the 40 mg-to-80 mg titration sequence and the safety-monitoring decisions claimed in the patent. Its position is narrower if a competitor omits the claimed indication, uses a different dosing schedule, or markets a product under a label that does not encourage the claimed monitoring and discontinuation steps.
What generic entry risks exist for valbenazine?
Paragraph IV litigation risk
A generic applicant seeking approval for valbenazine for tardive dyskinesia could use a Paragraph IV certification against listed patents. The applicant would typically argue one or more of the following:
- the patent claims are invalid for anticipation or obviousness;
- the claims lack adequate written description or enablement;
- the generic label does not induce performance of the claimed monitoring steps;
- the proposed product uses a different salt or polymorph;
- the claimed treatment protocol was already disclosed in the prior art; or
- the claims are not infringed because the generic label omits the relevant instruction.
The patent holder could respond that the generic label reproduces the claimed dosing regimen and safety instructions, making induced infringement foreseeable under 35 U.S.C. § 271(b).
Section viii carve-out risk
A section viii strategy may be difficult where the generic applicant seeks the same tardive dyskinesia indication and the approved labeling includes the same 40 mg initiation, dose escalation, and hypersensitivity warnings. A carve-out is more viable only if the applicant can remove the patented use without removing information necessary for safe and effective use of the unpatented indication or dosing regimen.
Product and process design-around
Potential design-around approaches include:
- using a non-ditosylate salt;
- using a different polymorphic form;
- selecting a different dosage form;
- seeking a label without the claimed titration instructions;
- omitting the patented use where legally and commercially feasible; or
- challenging the claims while retaining the FDA-approved indication.
These approaches may avoid particular dependent claims but are unlikely to eliminate exposure under the broader claims if the product remains valbenazine administered to treat tardive dyskinesia with the claimed monitoring process.
What patent litigation and settlement issues affect valbenazine?
The principal litigation risk is likely to arise when an ANDA applicant provides a Paragraph IV notice concerning Orange Book-listed valbenazine patents. The litigation analysis should distinguish:
- validity challenges to the compound or salt patents;
- infringement disputes concerning the commercial formulation;
- method-of-use disputes involving the tardive dyskinesia label;
- patent-term disputes; and
- settlement agreements that may provide a future generic entry date.
A settlement may allow an authorized generic, licensed generic, or agreed later entry before patent expiration. The commercial effect depends on whether the agreement includes a launch date, supply arrangement, license scope, or restrictions on product formulation and indications.
No conclusion about a specific settlement or active case should be inferred solely from the claims supplied. The patent itself does not disclose the outcome of later litigation or the commercial terms of any agreement.
How does Patent 11,026,931 compare with formulation and compound patents?
Patent 11,026,931 is narrower than a valid composition-of-matter patent but may be more directly aligned with an approved label.
| Protection type |
Breadth |
Main vulnerability |
| Compound patent |
High |
Expiration, validity, prior-art chemistry |
| Salt patent |
Medium to high |
Alternative salts and salt-selection arguments |
| Polymorph patent |
Medium |
Non-infringing solid forms and characterization disputes |
| Formulation patent |
Medium |
Excipients, release profile, and product differences |
| Method-of-use patent 11,026,931 |
Narrow to medium |
Label omission, induced-infringement, obviousness, claim construction |
| Manufacturing patent |
Variable |
Alternative synthetic routes and process proof |
The patent’s value is concentrated in the overlap between its claimed protocol and the FDA label. A generic can avoid a formulation claim by changing excipients, but avoiding a method claim may require a different label or a litigation-based launch strategy.
What is the FDA regulatory status of Ingrezza?
FDA approved Ingrezza for the treatment of tardive dyskinesia in 2017. The product is administered orally and is available in valbenazine capsules. The FDA-approved labeling includes a 40 mg starting dose and an increase to 80 mg once daily after one week for appropriate patients, with dose adjustment considerations for certain patient populations.[2]
The label also identifies hypersensitivity-related safety information, including angioedema and other hypersensitivity events. That overlap gives Patent 11,026,931 a direct regulatory connection to the approved product label.
What revenue exposure does the patent create?
The economic exposure is tied to continued branded sales of Ingrezza for tardive dyskinesia. The patent does not independently protect all Ingrezza revenue because other patents, regulatory exclusivities, formulation rights, and commercial factors may also affect entry.
The highest-value protected segment is the on-label US tardive dyskinesia market using:
- oral valbenazine;
- once-daily dosing;
- 40 mg initiation;
- escalation to 80 mg after one week; and
- safety monitoring for hypersensitivity reactions.
A generic launch that successfully avoids this patent but remains blocked by a compound, salt, polymorph, or formulation patent would not achieve commercial entry. Conversely, expiration or invalidation of this patent would not necessarily remove all barriers to valbenazine launch.
Key Takeaways
- US Patent 11,026,931 is a valbenazine method-of-use patent for tardive dyskinesia.
- The claims require monitoring for hypersensitivity reactions and discontinuing or continuing treatment based on the monitoring result.
- Claim 23 specifically covers 40 mg once daily for one week followed by 80 mg once daily.
- Dependent claims cover 40 mg, 60 mg, and 80 mg doses, tablets or capsules, valbenazine ditosylate, and ditosylate polymorphic Form I.
- The patent does not broadly claim valbenazine, all VMAT2 inhibitors, or every valbenazine formulation.
- Its expected term extends to approximately March 2038, subject to the official USPTO and Orange Book records.
- The principal generic risk is a Paragraph IV challenge involving the tardive dyskinesia indication and FDA-approved dosing label.
- Label-based induced-infringement and section viii carve-out issues are likely to be central.
- The patent must be analyzed with the broader Ingrezza compound, salt, polymorph, formulation, manufacturing, and method-of-use estate.
FAQs
Does US Patent 11,026,931 cover valbenazine for Huntington’s disease?
No. The supplied claims are directed to treating tardive dyskinesia. They do not expressly claim Huntington’s disease.
Does the patent cover a valbenazine injection?
Not under the tablet-or-capsule dependent claims. The independent claims are focused on administration of valbenazine in the claimed treatment protocol, while claims 5 and 12 specifically narrow the dosage form to a tablet or capsule.
Can a generic use a different valbenazine salt?
Possibly, but a different salt would not automatically avoid the independent claims, which cover valbenazine and pharmaceutically acceptable salts. It could avoid claims limited specifically to valbenazine ditosylate or polymorphic Form I.
Is the 60 mg dose required by the patent?
No. The patent identifies 60 mg as one alternative dose in claims 1 and 3 and related dependent claims. The principal titration claim uses 40 mg followed by 80 mg.
Does patent expiration automatically permit generic Ingrezza launch?
No. Launch timing also depends on other listed patents, regulatory exclusivity, litigation outcomes, settlement terms, patent-term adjustments, and the generic applicant’s certification strategy.
References
- United States Patent and Trademark Office. (2021). U.S. Patent No. 11,026,931, Methods of treating tardive dyskinesia.
- U.S. Food and Drug Administration. (2024). Ingrezza (valbenazine) prescribing information. Neurocrine Biosciences, Inc.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- 35 U.S.C. §§ 271, 281, 283, 284, 355(j).
- 21 C.F.R. §§ 314.50, 314.94, 314.127.
